Diamyd Signs Agreement With NIDDK for Diabetes Vaccine Trial

Diamyd Medical has executed an agreement with the National Institute of Diabetes and Digestive and Kidney Diseases for a planned clinical study with the Diamyd GAD-alum diabetes vaccine in 126 new onset type I diabetes patients.

Under the terms of the agreement, Diamyd Medical will supply clinical-grade material (i.e., Diamyd and placebo) for the trial. The clinical study will be conducted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsored consortium type I diabetes TrialNet.

Anders Essen-Mller, CEO of Diamyd Medical, said: “We are extremely excited to be working with NIDDK and TrialNet on this new Diamyd clinical study. TrialNet is uniquely positioned to conduct clinical studies and to evaluate the molecular and cellular mechanisms of potential diabetes therapies. The insights expected from this trial should prove very valuable for Diamyd, the scientific community and for diabetes patients.”